BRPI0412769A - combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor - Google Patents

combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor

Info

Publication number
BRPI0412769A
BRPI0412769A BRPI0412769-2A BRPI0412769A BRPI0412769A BR PI0412769 A BRPI0412769 A BR PI0412769A BR PI0412769 A BRPI0412769 A BR PI0412769A BR PI0412769 A BRPI0412769 A BR PI0412769A
Authority
BR
Brazil
Prior art keywords
tumor
treatment
bone loss
induced
bisphosphonate
Prior art date
Application number
BRPI0412769-2A
Other languages
English (en)
Inventor
Johann Zimmermann
Carsten Goessl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412769(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412769A publication Critical patent/BRPI0412769A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMBINAçõES DE UM INIBIDOR DE CATEPSINA K E UM BISFOSFONATO NO TRATAMENTO DE METáSTASE óSSEA, CRESCIMENTO DE TUMOR E PERDA óSSEA INDUZIDA POR TUMOR". A presente invenção refere-se a preparações farmacêuticas compreendendo certos tipos de bisfosfonatos e certos tipos de inibidores de catepsina K, em particular na prevenção e tratamento de metástases ósseas, hipercalcemia induzida por tumor, crescimento de tumor, perda óssea induzida por tumor e doenças de perda óssea tal com osteoporose ou perda óssea induzida por terapia de câncer.
BRPI0412769-2A 2003-07-21 2004-07-20 combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor BRPI0412769A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48892503P 2003-07-21 2003-07-21
PCT/EP2004/008107 WO2005014006A1 (en) 2003-07-21 2004-07-20 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Publications (1)

Publication Number Publication Date
BRPI0412769A true BRPI0412769A (pt) 2006-09-26

Family

ID=34135094

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412769-2A BRPI0412769A (pt) 2003-07-21 2004-07-20 combinações de um inibidor de catepsina k e um bisfosfonato no tratamento de métastase óssea, crescimento de tumor e perda óssea induzida por tumor

Country Status (21)

Country Link
US (1) US20060281714A1 (pt)
EP (1) EP1651238A1 (pt)
JP (1) JP2006528151A (pt)
KR (1) KR20060037382A (pt)
CN (1) CN100406016C (pt)
AR (1) AR045728A1 (pt)
AU (1) AU2004262903B2 (pt)
BR (1) BRPI0412769A (pt)
CA (1) CA2532948A1 (pt)
CO (1) CO5680441A2 (pt)
EC (1) ECSP066293A (pt)
IL (1) IL172913A0 (pt)
IS (1) IS8311A (pt)
MA (1) MA27925A1 (pt)
MX (1) MXPA06000790A (pt)
NO (1) NO20060851L (pt)
PE (1) PE20050328A1 (pt)
RU (1) RU2006105100A (pt)
TN (1) TNSN06021A1 (pt)
TW (1) TW200510436A (pt)
WO (1) WO2005014006A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686995A1 (en) * 2003-11-19 2006-08-09 Novartis AG Use of cathepsin k inhibitors for treating of severe bone loss diseases
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080219996A1 (en) * 2005-09-26 2008-09-11 Thea Kalebic Molecular Markers Associated with Bone Metastasis
JPWO2009054454A1 (ja) * 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US20210298890A1 (en) 2018-06-27 2021-09-30 Cirlo Gmbh Implants for recruiting and removing circulating tumor cells
US20230046007A1 (en) 2019-12-17 2023-02-16 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
WO2023212104A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Methods and agents for preventing skeletal aging, osteoporosis and obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
HK1039110A1 (zh) * 1999-03-15 2002-04-12 Axys Pharmaceuticals, Inc. 以新颖的合成物及组分作为蛋白酶抑制剂
EP1178810B8 (en) * 1999-05-21 2005-07-27 Novartis AG Use of bisphosphonic acids for treating angiogenesis
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
DE60225316T2 (de) * 2001-11-13 2009-02-26 AXYS Pharmaceuticals, Inc., South San Francisco Cyanoalkylamino-derivate als protease-hemmer

Also Published As

Publication number Publication date
CA2532948A1 (en) 2005-02-17
EP1651238A1 (en) 2006-05-03
MA27925A1 (fr) 2006-06-01
NO20060851L (no) 2006-04-21
MXPA06000790A (es) 2006-04-07
CN100406016C (zh) 2008-07-30
IS8311A (is) 2006-02-17
WO2005014006A1 (en) 2005-02-17
JP2006528151A (ja) 2006-12-14
TNSN06021A1 (en) 2007-10-03
US20060281714A1 (en) 2006-12-14
CO5680441A2 (es) 2006-09-29
AU2004262903A1 (en) 2005-02-17
KR20060037382A (ko) 2006-05-03
TW200510436A (en) 2005-03-16
RU2006105100A (ru) 2007-09-20
CN1826124A (zh) 2006-08-30
IL172913A0 (en) 2006-06-11
AU2004262903B2 (en) 2007-08-23
ECSP066293A (es) 2006-07-28
AR045728A1 (es) 2005-11-09
PE20050328A1 (es) 2005-06-16

Similar Documents

Publication Publication Date Title
TR199800767T2 (xx) Proteaz engelleyicileri.
CY1107927T1 (el) Ενωσεις φωσφονικου
SE9901272D0 (sv) New improved formulation
ATE409482T1 (de) Cathepsincystein-proteasehemmer
BR0115696A (pt) Uso de bisfosfonatos para tratamento de dor
DE60321141D1 (en) Cathepsin-cystein-protease-hemmer
TR199902703T2 (xx) Proteaz inhibit�rleri.
DZ2977A1 (fr) 4-Amino-azépam-3-ones inhibitrices de protéases, et compositions pharmaceutiques les contenant.
UY26625A1 (es) Inhibidores de proteasas
DK0756484T3 (da) Vådgranuleringsformulering til diphosphonsyrer
CY1109596T1 (el) Αναστολεις φωσφατασων cdc25
TNSN06021A1 (en) Combinations of cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
MXPA02012442A (es) Inhibidores de proteasa.
BR0209360A (pt) Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
IL161090A0 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonate, a cox-2 inhibitor and a taxol
WO2000059485A3 (en) Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
UY27032A1 (es) Inhibidores de proteasas
BR0307021A (pt) Uso de alquilfosfocolinas no tratamento preventivo de doenças de protozoários
ECSP982486A (es) Inhibidores de proteasas ii
UY26771A1 (es) Inhibidores de proteasas
ECSP982481A (es) Inhibidores de proteasas
ECSP982493A (es) Inhibidores de proteasas iii
MY139221A (en) Cathepsin cysteine protease inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012.